Trial Profile
A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC 673089) Versus Weekly Paclitaxel With Oncolytic Reovirus (Reolysin NSC 729968) in the Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Pelareorep (Primary) ; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 29 Aug 2020 Status changed from active, no longer recruiting to completed.
- 12 Sep 2017 Results (n=563) of pooled data from eight trial (NCI-GOG 0186H, NCI-8601, NCIC-CTG IND.213, REO011, REO015, REO016, REO018 and REO021) assessing the safety and tolerability of intravenous pelareorep in combination with chemotherapy, were presented at the 42nd European Society for Medical Oncology Congress.
- 27 Jul 2017 Results (n=108;from December 2010 to September 2014) published in the Gynecologic Oncology.